Takeda Pharmaceutical Company Limited (TAK) announced positive results from its Phase 2b trial of TAK-279, an investigational oral allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with active psoriatic arthritis. The study met its primary endpoint with 53.3% and 54.2% of patients treated with TAK-279 achieving at least an ACR 20 response compared to 29.2% in the placebo group at week 12. Takeda plans to initiate Phase 3 studies in plaque psoriasis in FY23 and psoriatic arthritis in FY24, while exploring TAK-279 in systemic lupus erythematosus, inflammatory bowel disease and other indications.